BioSig Technologies, Inc. (BSGM)
2025-06-30 | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Revenue | - | - | 13 | |
| Depreciation and amortization | - | - | 49 | |
| Research and development | 19 | 156 | 342 | |
| Impairment of long term assets | - | - | - | |
| General and administrative | 19,792 | 2,763 | 4,914 | |
| Depreciation and amortization | 554 | 31 | - | |
| Total operating expenses | 20,365 | 2,950 | 5,305 | |
| Loss from operations | -20,365 | -2,950 | -5,292 | |
| Other income (expense), net | -13 | 15 | -2 | |
| Interest income, net | 13 | - | -5 | |
| Gain (loss) on settlement and forgiveness of debt | -3 | 1,021 | 1,388 | |
| Total other income (expense), net | -3 | - | - | |
| Loss before income taxes | -20,368 | -1,914 | -3,911 | |
| Income taxes (benefit) | - | - | - | |
| Net loss | -20,368 | -1,914 | -3,911 | |
| Non-controlling interest | 4 | - | 4 | |
| Net loss attributable to biosig technologies, inc | -20,372 | -1,914 | -3,915 | |
| Preferred stock dividend | 2 | 2 | 3 | |
| Preferred stock deemed dividend | - | 24 | - | |
| Net loss attributed to biosig technologies, inc. common shareholders | -20,374 | -1,940 | -3,918 | |
| Net loss per common share, basic | -0.74 | -0.12 | -0.3 | |
| Net loss per common share, diluted | -0.74 | -0.12 | -0.3 | |
| Weighted average number of common shares outstanding, basic | 27,706,780 | 16,200,928 | 12,916,272 | |
| Weighted average number of common shares outstanding, diluted | 27,706,780 | 16,200,928 | 12,916,272 | |